Rinucumab

Rinucumab
Monoclonal antibody
Type	?
Source	Human
Target	platelet-derived growth factor receptor beta
Clinical data
ATC code	none
Identifiers
CAS Number	1569263-06-4
ChemSpider	none
Chemical and physical data
Formula	C₆₄₇₂H₉₉₇₄N₁₇₁₀O₂₀₂₂S₃₈
Molar mass	145.3 kg/mol

Rinucumab is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.^[1]

This drug was developed by Regeneron Pharmaceuticals, Inc.

References

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone ("-os-", "-s(o)-")

Human ("-mulu-")	Stamulumab^†

Circulatory ("-c(i[r])-")

Human ("-ciru-")	Alirocumab Ascrinvacumab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab Vesencumab

Mouse ("-ciro-")	Biciromab^‡ Imciromab^‡

Chimeric ("-cixi-")	Abciximab Volociximab

Humanized ("-cizu-")	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Etaracizumab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic ("-ne(u)(r)-")

Human ("-neru-")	Aducanumab Atinumab Erenumab Fasinumab Fulranumab Gantenerumab Opicinumab

Humanized ("-nezu-"/"-neuzu-")	Bapineuzumab^† Crenezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Solanezumab Tanezumab

Humanized ("-anibizu-")	Ranibizumab

Human ("-gru-")	Bimagrumab

Humanized ("-grozu-")	Domagrozumab Landogrozumab

This article is issued from Wikipedia - version of the 2/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.